China Resources Pharmaceutical Group Future Growth
Future criteria checks 1/6
China Resources Pharmaceutical Group is forecast to grow earnings and revenue by 6.3% and 7.8% per annum respectively. EPS is expected to grow by 6% per annum. Return on equity is forecast to be 8.2% in 3 years.
Key information
6.3%
Earnings growth rate
6.0%
EPS growth rate
Pharmaceuticals earnings growth | 12.7% |
Revenue growth rate | 7.8% |
Future return on equity | 8.2% |
Analyst coverage | Good |
Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 314,588 | 5,016 | 8,351 | 7,758 | 6 |
12/31/2025 | 287,990 | 4,721 | 6,300 | 8,791 | 9 |
12/31/2024 | 258,933 | 4,219 | 4,798 | 11,662 | 8 |
12/31/2023 | 244,704 | 3,854 | 12,550 | 15,550 | N/A |
9/30/2023 | 239,207 | 3,722 | 9,931 | 12,658 | N/A |
6/30/2023 | 247,532 | 3,852 | 7,840 | 10,729 | N/A |
3/31/2023 | 228,091 | 3,634 | 7,785 | 10,594 | N/A |
12/31/2022 | 218,183 | 3,500 | 8,239 | 10,821 | N/A |
9/30/2022 | 221,487 | 3,724 | 7,431 | 10,371 | N/A |
6/30/2022 | 211,788 | 3,719 | 6,240 | 9,347 | N/A |
3/31/2022 | 196,226 | 3,288 | 6,935 | 9,628 | N/A |
12/31/2021 | 193,021 | 3,072 | 8,009 | 10,468 | N/A |
9/30/2021 | 191,495 | 2,869 | 5,958 | 8,155 | N/A |
6/30/2021 | 187,554 | 2,626 | 3,792 | 5,694 | N/A |
3/31/2021 | 179,512 | 2,720 | 4,521 | 6,344 | N/A |
12/31/2020 | 168,762 | 2,776 | 5,194 | 6,910 | N/A |
9/30/2020 | 171,873 | 2,683 | 6,986 | 8,696 | N/A |
6/30/2020 | 174,956 | 2,578 | 8,914 | 10,616 | N/A |
3/31/2020 | 181,054 | 2,793 | 7,272 | 9,038 | N/A |
12/31/2019 | 182,690 | 2,937 | 5,488 | 7,274 | N/A |
9/30/2019 | 183,417 | 3,670 | 5,658 | 7,406 | N/A |
6/30/2019 | 173,938 | 4,187 | 5,510 | 7,124 | N/A |
3/31/2019 | 165,679 | 3,737 | 5,370 | 6,990 | N/A |
12/31/2018 | 166,626 | 3,494 | 5,528 | 7,244 | N/A |
9/30/2018 | 163,734 | 3,466 | 4,984 | 6,419 | N/A |
6/30/2018 | 154,852 | 3,309 | 4,276 | 5,387 | N/A |
3/31/2018 | 142,296 | 2,959 | 3,266 | 4,493 | N/A |
12/31/2017 | 143,688 | 2,901 | 2,586 | 4,045 | N/A |
9/30/2017 | 143,252 | 2,759 | N/A | 1,486 | N/A |
6/30/2017 | 142,276 | 2,602 | N/A | -1,189 | N/A |
3/31/2017 | 142,003 | 2,577 | N/A | 1,219 | N/A |
12/31/2016 | 140,316 | 2,526 | N/A | 3,689 | N/A |
9/30/2016 | 132,253 | 2,161 | N/A | 4,391 | N/A |
6/30/2016 | 129,313 | 1,889 | N/A | 5,222 | N/A |
3/31/2016 | 123,770 | 2,103 | N/A | 5,027 | N/A |
12/31/2015 | 122,785 | 2,388 | N/A | 5,017 | N/A |
12/31/2014 | 108,575 | 2,116 | N/A | 3,349 | N/A |
12/31/2013 | 91,313 | 2,061 | N/A | 3,203 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3320's forecast earnings growth (6.3% per year) is above the savings rate (2.2%).
Earnings vs Market: 3320's earnings (6.3% per year) are forecast to grow slower than the Hong Kong market (11.7% per year).
High Growth Earnings: 3320's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3320's revenue (7.8% per year) is forecast to grow slower than the Hong Kong market (8.2% per year).
High Growth Revenue: 3320's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3320's Return on Equity is forecast to be low in 3 years time (8.2%).